#1Passion for Innovation. Compassion for Patients™M FY2022 01 Financial Results Presentation DAIICHI SANKYO CO., LTD. Hiroyuki Okuzawa Director, Senior Executive Officer, CFO July 29, 2022 Daiichi-Sankyo#2Forward-Looking Statements Daiichi-Sankyo Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward-looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward. Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation. Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof. The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain. This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere. This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion. Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information. 2#3Agenda FY2022 Q1 Financial Results 2 Business Update 3 R&D Update 4 Appendix Daiichi-Sankyo 3#4Overview of FY2022 Q1 Results 0000 FY2021 Q1 Results FY2022 Q1 YOY (Bn JPY) Results Revenue Cost of sales * SG&A expenses * 264.1 280.3 +6.2% 16.2 85.2 74.7 -10.5 81.2 96.3 15.1 R&D expenses * 54.0 74.9 20.9 Core operating profit * 43.7 34.4 -21.3% -9.3 Temporary income * 2.1 0.0 -2.1 Temporary expenses * 0.0 -0.0 Operating profit 45.8 34.4 -24.9% -11.4 Profit before tax 47.1 29.4 -17.6 Profit attributable to owners 35.2 18.9 -46.5% -16.4 of the Company Currency Rate USD/JPY EUR/JPY 109.49 131.95 129.57 138.10 +20.08 +6.15 Daiichi-Sankyo As an indicator of ordinary profitability, "core operating profit" which excludes temporary income and expenses from operating income is disclosed. Income and expenses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses". Temporary income and expenses are excluded from results and forecast for cost of sales, SG&A expenses and R&D expenses shown in the list above. The adjustment table from operating profit to core operating profit is stated in the reference data 4#5Revenue Increased by 16.2 Bn JPY (Decreased by 1.1 Bn JPY excl. forex impact) Daiichi-Sankyo Positive Factors (Bn JPY) Negative Factors FY2021 Q1 Results Japan Business (incl. Innovative Pharmaceuticals, Generic, Vaccines, OTC) Oncology Business*1 American Regent EU Specialty Business 264.1 Japan Business Unit Lixiana 18.1 Tarlige +2.2 +1.8 Nexium -19.7 8.8 Daiichi Sankyo Espha +1.0 Vaccines business -0.9 0.7 | Oncology Business*1 Unit Enhertu +11.8 Olmesartan -1.5 2.8 ASCA American Regent Unit 1.6 (Asia, South and Central America) Venofer +2.5 Injectafer -2.9 Enhertu, Dato-DXd*2 GE injectables +1.0 3.1 Upfront Payment & Regulatory Milestone EU Specialty Business Unit Lixiana +3.9 Forex Impact*3 17.3 Gain on sales of transferring long-listed products -1.1 FY2022 Q1 Results 280.3 Positive Factors Negative Factors *1 Revenue for Daiichi Sankyo, Inc. and Daiichi Sankyo Europe's oncology products *2 Dato-DXd: Datopotamab deruxtecan (DS-1062) *3 Forex impact USD: +11.5, EUR: +1.9, ASCA: +3.8 Enhertu, Dato-DXd*² Upfront Payment & Regulatory Milestone Enhertu Regulatory Milestone +2.8 5#6Core Operating Profit Decreased by 9.3 Bn JPY (Decreased by 9.1 Bn JPY excl. forex impact) FY2021 Q1 Results 43.7 Revenue Cost of Sales SG&A Expenses R&D Expenses Forex Impact FY2022 Q1 Results 34.4 17.4 16.2 14.4 Positive Factors 14.2 7.9 Negative Factors Revenue +16.2 incl. forex impact of +17.3 Cost of Sales -14.2 Daiichi-Sankyo (Bn JPY) Improvement in cost of sales ratio by change in product mix SG&A Expenses +7.9 Increase in expenses related to Enhertu due to an increase in profit share of gross profit with AstraZeneca R&D Expenses +14.4 Increase in 3ADCS* R&D investments Forex Impact +17.4 (Profit Decreased) Cost of Sales +3.7 SG&A Expenses +7.2 R&D Expenses +6.5 * 3ADCs: 1) Enhertu, Trastuzumab deruxtecan (T-DXd, DS-8201), 2) Datopotamab deruxtecan (Dato-DXd, DS-1062) and 3) Patritumab deruxtecan (HER3-DXd, U3-1402) 6#7Profit Attributable to Owners of the Company Decreased by 16.4 Bn JPY FY2021 Q1 Results 35.2 Core Operating Profit Temporary Revenue/ Expenses Financial Income/ 6.2 Expenses etc. Income Taxes etc. 1.3▸ FY2022 Q1 Results 18.9 2.1 9.3 Temporary Revenue/Expenses Daiichi-Sankyo (Bn JPY) +2.1 (Profit Decreased) FY2021: Gains related to sale of Osaka logistics center (2.1) Financial Income/Expenses etc. +6.2 (Profit Decreased) . Deterioration in forex gains/losses +3.2 Deterioration in investment securities +2.8 valuation gains / losses Income Taxes etc. +1.3 Profit before Tax FY2021 Q1 47.1 FY2022 Q1 29.4 YOY -17.6 Income Taxes etc. 11.8 Tax rate 25.2% 10.6 35.9% -1.3 +10.7% Positive Factors Negative Factors 7#8Revenue: Business Units (incl. Forex Impact) Daiichi-Sankyo (Bn JPY) 0000 Japan Business FY2021 Q1 FY2022 Q1 YOY Results Results 129.1 109.0 -20.1 Daiichi Sankyo Healthcare 15.4 15.3 -0.1 Oncolgy Business 14.5 27.5 +13.1 Enhertu 10.8 26.7 +15.9 Turalio 0.6 0.8 +0.2 American Regent 39.1 47.0 +7.9 Injectafer 14.9 14.1 -0.8 Venofer 7.9 12.4 +4.5 GE injectables 13.8 17.6 +3.8 EU Speciality Business 32.7 37.1 +4.4 Lixiana 23.4 28.6 +5.2 Nilemdo/Nustendi 0.7 1.3 +0.6 Olmesartan 5.6 5.4 -0.2 ASCA (Asia, South and Central America) Business 26.5 31.9 +5.4 Currency Rate USD/JPY 109.49 129.57 +20.08 EUR/JPY 131.95 138.10 +6.15 8#9Revenue: Major Products in Japan (Bn JPY) FY2021 Q1 FY2022 Q1 YOY Results Results Lixiana anticoagulant 22.9 25.1 +2.2 Tarlige pain treatment 7.1 8.9 +1.8 Pralia treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis 9.2 9.9 +0.7 Efient antiplatelet agent 4.1 4.9 +0.7 Tenelia type 2 diabetes mellitus treatment 6.4 5.6 -0.8 Vimpat anti-epileptic agent 4.5 5.3 +0.8 Ranmark treatment for bone complications caused by bone metastases from tumors 5.1 4.9 -0.2 Canalia type 2 diabetes mellitus treatment 4.3 4.1 -0.3 Loxonin anti-inflammatory analgesic 5.8 4.6 -1.2 anti-cancer agent Enhertu 2.2 2.4 +0.3 (HER2-directed antibody drug conjugate) Emgality prophylaxis of migraine attacks 0.9 1.4 +0.6 Daiichi-Sankyo 9#10FY2021 Q1 Financial Results 2 Business Update 3 R&D Update 4 Appendix Daiichi-Sankyo 10#11ENHERTU Revenue 0000 FY2022 Q1 Results YOY FY2022 Forecast <Reference> YOY Total Consideration Product Sales 31.3 18.4 128.4 63.0 Japan US Europe ASCA Upfront payment Regulatory milestone payment US HER2+ Breast Cancer 3L 2.4 0.3 16.0 6.4 20.0 10.5 83.1 37.7 6.7 5.5 23.0 14.0 2.2 2.2 6.3 4.9 * 1 * 1 2.5 - 9.8 149.0 * 1 *1 3.4 2.8 20.6 18.3 100.3 0.2 0.9 13.7 EU HER2+ Breast Cancer 3L 0.1 0.5 7.9 US HER2+ Gastric Cancer 2L + 3L 0.2 0.8 12.1 US HER2+ Breast Cancer 2L 2.8 2.8 3.4 3.4 13.1 EU HER2+ Breast Cancer 2L 2.6 2.6 9.8 *2 22 US HER2-low Breast Cancer (post-chemo) 6.9 6.9 26.0 *2 EU HER2+ Gastric Cancer 2L 1.2 1.2 4.6 *2 US HER2+ or HER2 Mutant NSCLC 2L 4.3 4.3 13.1 *2 Quid related payment 0.3 *1 0.3 1.1 *1 -2.3 17.2 Total 37.4 21.4 159.9 79.1 266.5 *1 Revenue recognized in each period (Bn JPY) *2 Revenue based on the assumption that milestone will be achieved in FY2022; Expected consideration converted with forex rate of 130 JPY to 1 USD Daiichi-Sankyo 11#12Daiichi-Sankyo ENHERTU Performance in Each Region (US, EU) Steady increase in product sales due to market penetration and additional indication Global product sales: FY2022 Q1 results 31.3 Bn JPY (YOY +18.4 Bn JPY) FY2022 forecast 128.4 Bn JPY (YOY +63.0 Bn JPY) US Product sales: FY2022 Q1 results 20.0 Bn JPY (155 Mn USD) FY2022 forecast 83.1 Bn JPY (639 Mn USD) Indication: HER2+ BC 2L/3L, HER2+ GC 2L Market share status HER2+ BC 3L: Maintaining No.1 new patient share HER2+ BC 2L: Achieving No.1 new patient share already HER2+ GC 2L: Achieving No.1 new patient share Other progress ➤ Approved for HER2+ BC 2L and started promotion (May 2022) Classified as a category 1 preferred regimen for patients with tumors that are HER2 IHC 1+ or 2+ and ISH negative in NCCN*1 guidelines (Jun. 2022) Europe Product sales: FY2022 Q1 results 6.7 Bn JPY (52 Mn USD) FY2022 forecast 23.0 Bn JPY (177 Mn USD) Indication: HER2+ BC 2L/3L Market share status HER2+ BC 3L: Maintaining No.1 new patient share (UK, France, Germany) Other progress Approved for HER2+ BC 2L and started promotion (Jul. 2022) ENHERTU® trastuzumab deruxtecan *1 NCCN: National Comprehensive Cancer Network 12#13Daiichi-Sankyo ENHERTU Performance in Each Region (Japan, ASCA) Steady increase in product sales due to market penetration and increasing launched countries/regions Global product sales: FY2022 Q1 results 31.3 Bn JPY (YOY +18.4 Bn JPY) FY2022 forecast 128.4 Bn JPY (YOY +63.0 Bn JPY) Japan ASCA Product sales: FY2022 Q1 results 2.4 Bn JPY (19 Mn USD) FY2022 forecast 16.0 Bn JPY (123 Mn USD) Product sales: FY2022 Q1 results 2.2 Bn JPY (17 Mn USD) FY2022 forecast 6.3 Bn JPY (48 Mn USD) Indication: HER2+ BC 3L, HER2+ GC 3L Market share status ➤ HER2+ BC 3L: Maintaining No.1 new patient share HER2+ GC 3L: Maintaining No.1 new patient share Other progress Classified as a preferred regimen for HER2+ BC 2L treatment in guidelines (Jun.2022) Indication: HER2+ BC 2L/3L Market share status Sales growing in Brazil, Hong Kong and Taiwan Other progress Launched in Taiwan (Apr. 2022) ENHERTU® trastuzumab deruxtecan 13#14Initiatives Related to Profit Growth for Current Business and Products Daiichi-Sankyo Enhance product portfolio in Japan Business REYVOW® Migraine treatment ➤ Launched*1 in June 2022 *1 Eli Lilly Japan and Daiichi Sankyo signed an agreement on reverse co-promotion in which Eli Lilly Japan is responsible for clinical development and manufacturing and Daiichi Sankyo is in charge of distribution and sales, and the companies will co-promote the product. MINEBROⓇ Orally Disintegrating Tablet Antihypertensive agent ➤ Launched in May 2022 片線治療劑 5HT登自体作動開 30PTP (103) 30PTP (10×3) 国産 5-HT 「レイボー錠100mg (ラスミジテンコハク - Lilly 0 100mg 「レイボー錠50mg 50円 50mg イラスミジタンコハク ミネラルコルチコイド ブロッカー E7DOD 1.25mg エサキセレノン 0 1002 100度 ミネラルコルチコイドブロッカー 100 ミネラルコルチコイドブロッカー ミネブロOD錠2.5mg ミネブロOD錠5mg エサキセレノン製剤 エサキセレノン製剤 OD 2.5mg OD 5mg MINNEBRO OD 1.25mg MINNEBRO Enhance transformation into a profit structure focused on patented drugs Concluded an asset sale agreement in Europe Divested Products: EFIENT ® Antiplatelet agent (FY2021 Revenue: 1.5 Bn JPY) Date of Agreement: June 2022 New Owner Substipharm 14 14#151 FY2021 Q1 Financial Results 2 Business Update 3 R&D Update 4 Appendix Daiichi-Sankyo 15#163ADC Update Alpha Update News Flow Daiichi-Sankyo 16#17ENHERTU DESTINY-Breast04 study Daiichi-Sankyo Pioneer HER2 low BC as a new clinically meaningful patient segment ■ENHERTUⓇ met the primary endpoint and all key secondary endpoints in the global Ph3 study for patients with HER2 low breast cancer previously treated with chemotherapy ■ENHERTUⓇ is the first and only HER2-directed therapy to demonstrate a survival benefit for patients with HER2 low breast cancer. In Jun 2022, ENHERTUⓇ was listed in US NCCN guidelines as preferred regimen (category 1) for HER2 low breast cancer previously treated with chemotherapy ■ About 50% of all breast cancer patients are reclassified as HER2 low, a new targetable patient segment Regulatory submission status in each countries ― Jun 2022: Filing accepted in JP & EU - Jul 2022: Filing accepted and granted priority review in US (PDUFA date Nov 26) - FY2022 Q2: Filing planned in China HER2 positive IHC 3+ IHC 2+/ISH+ HER2 low IHC 2+/ISH- IHC 1+ ~50% HER2 negative IHC<1+ BC: breast cancer, NCCN: National Comprehensive Cancer Network 17#18ENHERTU DESTINY-Breast04 data ASCO 2022 Highlights (Plenary Session) PFS in patients with HR+/HER2 low BC 49% reduction in the risk of disease progression or death versus chemo, mPFS of 10.1m compared to 5.4m with chemo PFS (HR+) 100 Hazard ratio: 0.51 95% CI, 0.40-0.64 P < 0.0001 PFS in all patients with HR+ or HR-/HER2 low BC ■50% reduction in the risk of disease progression or death versus chemo, mPFS of 9.9m compared to 5.1m with chemo PFS (All patients) 100 80 Hazard ratio: 0.50 95% CI, 0.40-0.63 P < 0.0001 Progression-Free Survival Probability (%) 20 40 60 80 TPC A 4.7 mo T-DXd mPFS: 10.1 mo mPFS: 5.4 mo 4+1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Months Progression-Free Survival Probability (%) 60 A 4.8 mo 40 20 TPC mPFS: 5.1 mo T-DXd mPFS: 9.9 mo BC: breast cancer, HR: hormone receptor, mPFS: median progression-free survival, PFS: progression-free survival, T-DXd: trastuzumab deruxtecan, TPC: treatment of physician's choice 0 0 1 2 3 4 5 6 8 7 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Months 18 Daiichi-Sankyo#19ENHERTU DESTINY-Breast04 data ASCO 2022 Highlights (Plenary Session) Daiichi-Sankyo OS in patients with HR+/HER2 low BC 36% reduction in the risk of death versus chemo, mOS of 23.9m compared to 17.5m with chemo OS (HR+) OS in all patients with HR+ or HR-/HER2 low BC 36% reduction in the risk of death versus chemo, mOS of 23.4m compared to 16.8m with chemo OS (All patients) Overall Survival Probability (%) 100 60 10 40 20 20 Hazard ratio: 0.64 95% CI, 0.48-0.86 P = 0.0028 TPC MOS: 17.5 mo T-DXd MOS: 23.9 mo A 6.4 mo LI Overall Survival Probability (%) 100 80 60 40 40 20 Hazard ratio: 0.64 95% CI, 0.49-0.84 P = 0.0010 TPC MOS: 16.8 mo A 6.6 mo T-DXd MOS: 23.4 mo 0 0 T T T T 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 Months 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 Months BC: breast cancer, HR: hormone receptor, mOS: median overall survival, OS: overall survival, T-DXd: trastuzumab deruxtecan, TPC: treatment of physician's choice 19#20ENHERTU Development of HER2 low breast cancer Now conducting DESTINY-Breast06/08 studies in earlier lines of HER2 low breast cancer and further development is under discussion HR+/HER2 low BC Endocrine therapy + CDK4/6 inhibitor Chemotherapy 1L Chemotherapy 2L HR-/HER2 low BC Not Applicable BC: breast cancer, HR: hormone receptor DESTINY-Breast06 Ph3 DESTINY-Breast08 Ph1b, combination Daiichi-Sankyo Chemotherapy 3L DESTINY-Breast04 Ph3 DESTINY-Breast04 Ph3 DESTINY-Breast08 Ph1b, combination 20 10#21ENHERTU DESTINY-Breast06/08 studies ■DESTINY-Breast06 Ph3 study design Chemo naive HR+/HER2 low advanced or metastatic BC randomize 1:1 N = 850 ENHERTUⓇ Investigator's choice of chemo Endpoints: PFS, etc. Part 2 dose expansion ■DESTINY-Breast08 Ph1b study design Part 1 dose finding ENHERTU® + capecitabine ENHERTU® + durvalumab + paclitaxel HR+/HR- HER2 low ENHERTU® + capivasertib advanced or metastatic BC ENHERTU® + anastrozole N = 182 Endpoints: safety, efficacy, etc. BC: breast cancer, PFS: progression free survival ENHERTU® + fulvestrant Daiichi-Sankyo 21#22ENHERTU DESTINY-Breast03 safety data update ASCO 2022 Highlights The data reinforce the established favorable benefit/risk profile over T-DM1 in HER2+ BC Safety update overview (Sep 7, 2021) No new safety signals were observed for T-DXd Adjudicated drug-related ILD/pneumonitis ■No Gr4/5 ILD/pneumonitis occurred in the T-DXd arm Incidence rates of AEs were similar between the T-DXd and T-DM1 arms T-DXd T-DM1 n = 257 n = 261 n (%) Any grade, n (%) Patients discontinued from study treatment 141 (54.9) 222 (85.1) Grade 1 Grade 2 Any grade TEAE 256 (99.6) 249 (95.4) Grade 3 Grade 4 Grade 3 TEAE 137 (53.3) 130 (49.8) Grade 5 Any grade serious TEAE 54 (21.0) 50 (19.2) Time to first onset, median (range), days Outcome of worst event, n (%) Grade ≥3 serious TEAE 39 (15.2) 38 (14.6) Fatal Not recovered/not resolved TEAE associated with drug discontinuation 38 (14.8) 19 (7.3) Ongoing Recovering/resolving TEAE associated with dose reduction 59 (23.0) 36 (13.8) Recovered/resolved with sequelae Recovered/resolved AE: adverse events, BC: breast cancer, TEAE, treatment-emergent adverse event. T-DXd T-DM1 n = 257 n = 261 28 (10.9) 5 (1.9) 7 (2.7) 4 (1.5) 19 (7.4) 1 (0.4) 2 (0.8) 0 0 0 0 0 181 (33-507) 289 (80-499) 0 8 (28.6) 0 2 (7.1) 2 (7.1) 16 (57.1) 1 (20.0)a 0 0 0 4 (80.0) Daiichi-Sankyo aPatient had an event of pulmonary embolism that the investigator considered to be grade 5. This was initially reported as respiratory failure but subsequently updated to pulmonary embolism. The ILD adjudication committee adjudicated this event as drug-related grade 1 ILD/ pneumonitis. The death was not evaluable for adjudication. The investigator recorded disease progression as the primary cause of death.1 1. Cortés J et al. N Engl J Med. 2022;386:1143-1154 (supplementary appendix) . 22#23ENHERTU FY2022 approval status Daiichi-Sankyo HER2+ BC 2L ■May 2022: FDA approval based on Priority Review, Breakthrough Therapy Designation and Real Time Oncology Review program ■■■Jul 2022: EMA approval * Approval also obtained in the countries joining Project Orbis (Brazil, Australia, Israel, Canada, Switzerland) in FY2022 H1 BC: breast cancer 23#24Dato-DXd BEGONIA study interim data ESMO BC 2022 Highlights Daiichi-Sankyo Evidence of strong synergy between Dato-DXd and immune checkpoint inhibitor supports further development in TNBC Best change from baseline in target lesion size (%) 100- N=29 50- Anti-tumor activity Patients evaluable for 27 confirmed response³ Confirmed ORR, n (%) 20 (74) 95% CI 54-89 CR, n (%) 2 (7) PR, n (%) 18 (67) -50- I -100- PD-L1 expression (TAP 5% cutoff): High aHad the opportunity to have 2 postbaseline scans. Dotted lines indicate thresholds for partial response (-30%) and progressive disease (20%) *If the best percentage change from baseline of target lesions cannot be calculated due to progression, withdrawal, or death, the value is imputed at +20%. "." Patients with PD as best overall response. +CR with lymph node disease (CR per RECIST in lymph nodes, is <10mm) . Unconfirmed response. CR, complete response; ORR, objective response rate; PR, partial response, TNBC, triple negative breast cancer. Low Unknown/Missing t BEGONIA study Ph1b/2 study for TNBC 1L sponsored by AstraZeneca. Several drugs are tested for combination with durvalumab. ■Responses were observed regardless of PD-L1 expression, and confirmed ORR was 74% Combination of Dato-DXd + durvalumab demonstrated a safety profile which was consistent with known profile of the individual agents Part 1 is completed and enrollment of part 2 (expansion) is ongoing 24#25Dato-DXd New clinical study TROPION-Breast02 study (TNBC 1L, Ph3) started in Jun 2022, TROPION-PanTumor02 study (NSCLC/TNBC, Ph1/2, China only) started in Jul 2022 TROPION-Breast02 Ph3 study design Locally recurrent inoperable or metastatic TNBC 1L* *Patients who are not candidates for PD-1/PD-L1 inhibitor therapy randomize N = 600 1:1 Dato-DXd Investigator's choice of chemo Endpoints: PFS, OS, etc. ■TROPION-PanTumor02 Ph1/2 study design N = 118 Dato-DXd Endpoints: ORR, etc. Cohort 1: NSCLC Daiichi-Sankyo Cohort 2: TNBC Possibility to add new cohorts for other tumors in the future NSCLC: non small cell lung cancer, ORR: overall response rate, OS: overall survival, PFS: progression free survival, TNBC: triple negative breast cancer 25#26HER3-DXd Breast cancer Ph1/2 study data Daiichi-Sankyo ASCO 2022 Highlights Clinically meaningful and durable responses were observed across breast cancer subtypes, responses were seen across a broad range of HER3 expression Anti-tumor activities (HR+/HER2-, TNBC, HER2+ cohorts) ■ HR+/HER2- (ORR 30%, mDOR 7.2m), TNBC (ORR 23%, mDOR 5.9m), HER2+ (ORR 43%, mDOR 8.3m) 60 40 20 0 -20 -40 -60 -80 -100 60 40 20 0 -20 -40 -60 -80 -100 a Patients with TNBC and HER2+ were all HER3-high. TNBCa Patients (n=51) HR+/HER2- HER3 Expression High Low 60 HER2+a 40 20 0 -20 -40 -60 -80 -100 Patients (n=13) b Best percentage change from baseline in sum of diameters based on BICR for all target lesions identified is represented by patient. If any lesion measurement is missing at a post-baseline tumor assessment visit, that visit is not taken into consideration for best percent change from baseline in sum of diameters. DOR: duration of response, HR: hormone receptor, ORR: objective response rate, TNBC: triple negative breast cancer 26#27HER3-DXd NSCLC Ph1 study cohort 2 data ASCO 2022 Highlights Daiichi-Sankyo The promising clinical activity of HER3-DXd in patients with NSCLC harboring a broad range of genomic alterations or without genomic alterations Anti-tumor activity (With (A) or Without (B) genomic alterations) (A) (B) Best percentage change in sum of diameters -40 -80 2202488 -20 CR PR BOR by BICR SD PD NE + Treatment ongoing Outcomes (BICR per RECIST 1.1) Confirmed ORR (95% CI), % -60 Disease control rate (95% CI), % N=21 28.6 (11.3, 52.2) 76.2 (52.8, 91.8) Time to response, median (range), mo Duration of response, median (95% CI), mo PFS, median (95% CI), mo 2.8 (1.3-4.6) 9.4 (4 2-NE) 10.8 (2.8-16.0) -100 EGFR Driver genomic ERBB2 alteration AMP MET EGFR KRAS EGFR ERBB2 AMP Ex20ins G12C Ex20ins D769Y EGFR CD74: Ex20ins ROS1 KRAS CD74: G12D ROS1 EGFR Ex20ins T751 1759 delinsN EGFR KRAS L861R G12C ERBB2 A775_6776 inSYVMA RET fusion NRAS EML4 Q61L ALK KRAS EML4 G12F ALK ALK On-target resistance mechanism Off-target resistance mechanism ROS1 D2033N ROS1 G2032R ALK L1196M G1202R $1206F S1206Y BRAF V600E Best percentage change in sum of diameters CR PR BOR by BICR SD PD NE + Treatment ongoing 40 20 0 -20 -40 Outcomes (BICR per RECIST 1.1) N=26 -60 Confirmed ORR (95% CI), % Disease control rate (95% CI), % 26.9 (11.6, 47.8) 73.1 (52.2, 88.4) Time to response, median (range), mo -80 9.6 (1.6-NE) 4.2 (2.5-10.8) -100 + Cohort 2 Patients with advanced NSCLC without common EGFR mutations ■HER3-DXd showed promising clinical activity and manageable safety profile in patients with or without genomic alterations Presented cohort 1 data with EGFR mutations at last year's ASCO Duration of response, median (95% CI), mo PFS, median (95% CI), mo 2.1 (1.2-6.0) Data cutoff: January 28, 2022. Twenty of 21 patients with identified driver mutations, and 24 of 26 patients without, had best percentage change in sum of diameters data available. BICR: blinded independent central review, BOR: best objective response, NSCLC: non small cell lung cancer 27#283ADC Update Alpha Update News Flow Daiichi-Sankyo 28#29DS-7300 ES-SCLC Ph2 study Development update Ph2 dose-finding study for ES-SCLC was initiated in June Ph1/2 study design Dose escalation (Part 1) Advanced/unresectable or metastatic solid tumor (various types of cancer) 0.8 mg /kg 1.6 mg /kg 3.2 mg /kg 4.8 mg /kg Dose expansion (Part 2) [Cohort 1] ESCC [Cohort 2] CRPC [Cohort 3] Squamous NSCLC 6.4 mg /kg ES-SCLC Ph2 study design Daiichi-Sankyo DS-7300 8mg/kg 16.0 mg /kg 12.0 mg /kg ES-SCLC 2L or later randomize 1:1 DS-7300 12mg/kg 8.0 mg /kg Primary endpoint: ORR Secondary endpoint: PFS, DOR, OS, etc ES-SCLC was selected based on Ph1 data N = 80 Extensive stage (ES) means cancer spreads across a wide area and surgical operation and radiation therapy are not applicable No effective treatment and high unmet need for ES-SCLC 2L or later Efficacy and safety of two doses will be evaluated in Ph2 study in patients with ES-SCLC who received at least one prior line of platinum- based chemotherapy Option for addition of 60 patient expansion at RP2D CRPC: castration-resistant prostate cancer, DOR: duration of response, ESCC: esophageal squamous cell carcinoma, NSCLC: non small cell lung cancer, ORR: objective response rate, OS: overall survival, PFS: progression free survival, RP2D: recommended Ph2 dose, SCLC: small cell lung cancer 29 29#30Best change from baseline in sum of diameters, % DS-6000 Ovarian cancer/renal cell carcinoma Ph1 data ASCO 2022 Highlights Tolerability and preliminary efficacy were observed in the interim Ph1 data ■DS-6000 was generally well tolerated Daiichi-Sankyo DS-6000 demonstrated early clinical signals (RECIST and CA-125 responses) in heavily pretreated patients with advanced platinum-resistant OVC and RCC ■Expansion cohorts (part B) opened at 8.0 mg/kg are enrolling patients with OVC and RCC Anti-tumor activity (OVC, RCC) Change from baseline in CA-125* levels in patients with OVCa 80- 60- RCC renal cell carcinoma OVC = serous ovarian cancer 40- 20- 4.8 mg/kg 8.0 mg/kg OVC OVC RCC OVC OVC RCC OVC OVC OVC OVC OVC RCC OVC 0 RCC OVC OVC RCC OVC RCC OVC -20- -40- -60- -80- Best change from baseline in CA-125, % 80 60 SD 40 PD 20- b b b b b b b b 0 SD NA PR -20 -40 -60- -80 PR SD Non-CR/ Non-PD SD SD SD PR SD Non-CR/ -100 Non-PD PR SD PR -100- Starting dose level 1.6 mg/kg 3.2 mg/kg 4.8 mg/kg 6.4 mg/kg 18.0 mg/kg 19.6 mg/kg Starting dose level 1.6 mg/kg 3.2 mg/kg 4.8 mg/kg 6.4 mg/kg 8.0 mg/kg 9.6 mg/kg Data cutoff: February 25, 2022. CA-125, cancer antigen 125; CR, complete response; GCIG, Gynecologic Cancer InterGroup; NA, not available; OVC, ovarian cancer; PD, progressive disease; PR, partial response; SD, stable disease. a Patients with baseline CA-125 value and ≥1 postbaseline CA-125 value were included. b According to the GCIG criteria, patients can be evaluated for response only if they have a baseline sample that is ≥2 x the upper limit of normal obtained within 2 weeks prior to starting treatment. CA-125 response is defined as a ≥50% reduction in CA-125 levels from a pretreatment sample. The response must be confirmed and maintained for ≥28 days. *CA-125: Protein which express on endometrium and peritoneum. CA-125 level in blood increases in patients with gynopathy such as ovarian cancer and uterine cancer. 30#31DXd-ADC Technology Grand prize for 6th Bioindustry awards Significant efficacy of ENHERTUⓇ and future potential of DXd-ADC technology are recognized as breakthrough Japan Bioindustry Award バイオインダストリー大賞 DXd-ADC Technology Daiichi-Sankyo 5 researchers at Daiichi Sankyo received the grand prize for Bioindustry for "Innovation of New Generation Antibody Drug Conjugate Technology, DXD-ADC" ➤ This prize is to award an achievement which is expected to have a strong impact on the development of the fields of bioscience, biotechnology and bioindustry ➤ It is the first time that a company alone receive the prize ➤ General Incorporated Association Japan Bioindustry Association announced award on July 15, 2022 Award recipients: Toshinori Agatsuma (Head of Oncology Research Laboratories I, Corporate Officer) Yuki Abe (Head of Oncology Research Laboratories II) ➤ Hiroyuki Naito (Medicinal Chemistry Research Laboratories) Takashi Nakada (Oncology Research Laboratories I) Yusuke Ogitani (Oncology Research Laboratories II) Image is for illustrative purposes only; actual drug to antibody ratio and drug positions may vary. 31#32Quizartinib QUANTUM-First study data EHA 2022 Highlights (Presidential Symposium) Daiichi-Sankyo Quizartinib + SOC doubled OS in patients with AML 1L with FLT3-ITD mutation vs SOC, regulatory submission planned in FY2022 H1 in JP/US/EU Overall survival probability 1.0 0.8 0.6 Placeboc Primary Endpoint: OS 0.4 MOS: 15.1 mo AMOS: 16.8 mo 0.2 L HR, 0.776 (95% CI, 0.615-0.979) P=.0324 (2-sided) a Quizartinibb MOS: 31.9 mo …………-------- 0.0 T T T 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 Time, months QUANTUM-First study Ph3 study for patients with newly diagnosed AML with FLT3-ITD mutation ■Efficacy and safety were evaluated in quizartinib + standard chemotherapy arm and placebo + standard chemotherapy arm ■Quizartinib demonstrated a 22.4% reduction in the risk of death compared to standard chemotherapy alone ■Median OS of 31.9m compared to 15.1m with chemotherapy ■No new safety signals were observed a P value was calculated using a stratified log-rank test. b Median follow-up time for quizartinib arm, 39.2 months. c Median follow-up time for placebo arm, 39.2 months. AML: acute myeloid leukemia, OS: overall survival, SOC: standard of care 32#33DS-5670 Current development status Development of COVID-19 vaccine progressed FY2021 FY2022 H1 H2 H1 Ph1/2 study Ph1/2/3 booster vaccination Planning Ph3 study in Japan (JP) Dose setting Ph2 Development of initial vaccination = Dose setting Ph2 study ● • Results presented no significant safety concerns. The neutralizing antibody titers 14 days after the 2nd shot of DS-5670 have demonstrated adequate immunity. - Planning to start Ph3 study in Japan in FY2022 H1 Study design . Subjects: COVID-19 unvaccinated Japanese healthy adults • Randomized, non-controlled, parallel- group comparison study (30μg and 60µg) • Investigate safety, immunogenicity (anti- SARS-CoV-2 neutralizing activity of RBD IgG in blood, antibody titer) and PK H2 Daiichi-Sankyo 33#34DS-5670 Current development status Development of COVID-19 vaccine progressed FY2021 FY2022 H1 H2 H1 H2 Ph1/2 study Ph2 Ph1/2/3 booster vaccination Planning Ph3 study in Japan (JP) Dose setting ■Development of booster vaccination - Ph1/2/3 study Part 1 was completed - - Efficacy: Data on neutralizing activities four weeks after receiving the vaccination show that the efficacy of DS-5670 is comparable to or higher than an approved mRNA vaccine in both healthy adult and elderly subjects - Safety: no serious adverse reactions at the injection site or systemic ones were observed. · Part 2 was initiated in May 2022 - Commercialization in Japan is expected within CY2022 Part 1 Dose confirmation study (528 subjects) Part 2 Active-controlled, non-inferiority study (4500 subjects) Confirmatory study of booster effect comparing to approved COVID-19 mRNA vaccine in subjects who completed the initial vaccination (1st & 2nd shots) of approved COVID-19 mRNA vaccine Daiichi-Sankyo 34#35DS-2325 (KLK5 inhibitor) New clinical study Target Disease ■Netherton syndrome An autosomal recessive genetic disease affecting skin, hair and immune system - Caused by mutations in the SPINK5 gene, which encodes LEKTI, a serine protease inhibitor - Incidence is estimated at 1/200,000-1/300,000 births Development Stage Ph1 study started in June 2022 Randomized, placebo-controlled, double-blind study in healthy adults - Evaluate the safety, tolerability, and PK Mode of Action ■Skin of NS patient - - Desquamation - Inflammation DS-2325 (KLK5 inhibitor) KLK5 LEKTI (Loss-of-function mutations) Daiichi-Sankyo 35#363ADC Update Alpha Update News Flow Daiichi-Sankyo 36#37FY2022 Future News Flow Daiichi-Sankyo As of Jul 2022 Planned regulatory submissions DESTINY-Breast04: HER2 low BC, post chemo, Ph3 Planned major publications World Conference on Lung Cancer (WCLC, Aug 6-9, 2022) Dato-DXd TROPION-Lung02: NSCLC without actionable gene mutation, Ph1b, pembrolizumab combo • Initial interim data European Society for Medical Oncology (ESMO, Sep 9-13, 2022) DS-7300 Solid tumors Ph1/2 ENHERTUⓇ Quizartinib DS-5670 • Data update Regulatory decisions DESTINY-Breast03: HER2+ BC, 2L, Ph3 • JP: FY2022 H2 • US: FY2022 H2 ENHERTU ® DESTINY-Breast04: HER2 low BC, post chemo, Ph3 DESTINY-Gastric02: HER2+ GC, 2L, Ph2 • EU: FY2022 H2 DESTINY-Lung01: HER2 mutated NSCLC, 2L, Ph2 ⚫ US: FY2022 H1 Registrational Ph2: R/R ATL/L Valemetostat • JP: FY2022 H1 • CN: FY2022 H1 QUANTUM-First • AML, 1L, Ph3 JP/US/EU: FY2022 H1 Ph1/2/3: COVID-19 mRNA vaccine, booster shot ⚫ JP: FY2022 H2 Key data readouts ENHERTUⓇ DESTINY-Breast02: HER2+ BC, 3L, Ph3 . FY2022 H1 TROPION-Lung01*: NSCLC, 2/3L, Ph3 Dato-DXd • FY2022 H2 DS-5670 Ph1/2/3: COVID-19 mRNA vaccine, booster vaccination • FY2022 H2 Planned pivotal study initiation HER3-DXd HERTHENA-Lung02: EGFR mutated NSCLC, 2L, Ph3 • FY2022 H1 Bold: update from FY2021 Q4 AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, BC: breast cancer, GC: gastric cancer, NSCLC: non small cell lung cancer, R/R: relapsed/refractory Timeline indicated is based on the current forecast and subject to change. *Event-driven study 37#38Agenda 1 FY2022 Q1 Financial Results 2 Business Update 3 R&D Update 4 Appendix Daiichi-Sankyo 38#39Major R&D Milestones (3ADCs) Project ENHERTUⓇ Target Indication [phase, study name] • HER2+, 3L [P3, DESTINY-Breast02] • HER2+, 2L [P3, DESTINY-Breast03] FY2022 H1 • TLR anticipated • Approved (US/EU) BC GC NSCLC • • • HER2 low, Post chemo [P3, DESTINY-Breast04] HER2 low, chemo naïve [P3, DESTINY-Breast06] HER2+, 2L [P2, DESTINY-Gastric02, EU] HER2 mutated, 2L [P2, DESTINY-Lung01] HER2 mutated, 2L [P2, DESTINY-Lung05, CN] . Filing accepted (JP/US/EU) . Filing planned (CN) • Filing accepted (US) • Approval anticipated (US) • Study start planned NSCLC • 2/3L [P3, TROPION-Lung01] H2 HH As of Jul 2022 FY2023 Daiichi-Sankyo • Approval anticipated (JP) • Approval anticipated (US) • Approval anticipated (EU) • Approval anticipated (JP/EU) ⚫TLR anticipated • TLR anticipated Dato-DXd BC • TNBC, 1L, [P3, TROPION-Breast02] Solid tumors HER3-DXd NSCLC Bold: update from FY2021 Q4 • NSCLC, TNBC [P1/2, TROPION-Pan Tumor02, CN] • • • EGFR mutated, 3L [Registrational P2, HERTHENA-Lung01] EGFR mutated, 2L [P3, HERTHENA-Lung02] ⚫ Study started • Study started • Study start planned BC: breast cancer, GC: gastric cancer, NSCLC: non small cell lung cancer, TLR: top line results The timeline indicated is based on the current forecast and subject to change. • TLR anticipated 39#40Major R&D Milestones (Alpha) DS-7300 Project Quizartinib Valemetostat (DS-3201) DS-9606 • . • Target Indication [phase, study name] • ES-SCLC, 2L [P2, JP/US/EU/Asia] AML, 1L [P3, JP/US/EU/Asia] ATL/L [Registrational P2, JP] Solid tumors [P1, US/EU] • . H1 FY2022 Study started Filing anticipated (JP/US/EU) • Approval anticipated (JP) ⚫ Study started DS-2325 • Netherton syndrome [P1, US] DS-5670 • COVID-19 mRNA vaccine, booster [P1/2/3, JP] . • Study started H2 12 • TLR anticipated As of Jul 2022 Daiichi-Sankyo • Filing anticipated (JP) Bold: update from FY2021 Q4 AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, ES-SCLC: extensive stage-small cell lung cancer, TLR: top line results The timeline indicated is based on the current forecast and subject to change. FY2023 • Approval anticipated (JP/US/EU) 40#41Major R&D Pipeline: 3ADCs (US/EU/Asia) HER2+ BC 2L~/1L DESTINY-Breast07 (US/EU/Asia) HER2 low BC Chemo naïve/ post chemo DESTINY-Breast08 Phase 1 (JP/US/EU/Asia) HER2+ GC combo, 2L~/1L DESTINY-Gastric03 (EU/Asia) HER2+ NSCLC (durvalumab combo) 1L DESTINY-Lung03 (US/EU) BC, bladder (nivolumab combo) (US/EU) BC, NSCLC (pembrolizumab combo) (US/EU/Asia) solid tumors (AZD5305 combo) PETRA (JP/US) NSCLC, TNBC, HR+ BC, SCLC, urothelial, GC, esophageal, etc. TROPION-PanTumor01 (CN) NSCLC, TNBC TROPION-PanTumor02 (JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembrolizumab combo) TROPION-Lung02 (JP/US/EU) NSCLC (w/o actionable mutation, durvalumab combo) TROPION-Lung04 (US/EU/Asia) TNBC (durvalumab combo) BEGONIA (JP/US/EU/Asia) solid tumors (AZD5305 combo) PETRA (JP/US/EU/Asia) NSCLC Phase 2 (US/EU/Asia) TNBC (durvalumab combo) BEGONIA (CN) HER2+ GC 3L DESTINY-Gastric06 Phase 3 (JP/US/EU/Asia) HER2+ BC 3L DESTINY-Breast02 (JP/US/EU/Asia) HER2+ BC post neoadjuvant DESTINY-Breast05 (JP/US/EU/Asia) HER2 low BC chemo naive DESTINY-Breast06 (JP/US/EU/Asia) HER2+ BC 1L DESTINY-Breast09 As of Jul 2022 Filed (JP/US/EU/Asia) HER2+ BC 2L DESTINY-Breast03 (EU) HER2+ GC 2L DESTINY-Gastric02 (US) HER2 mutated NSCLC 2L~ DESTINY-Lung01 (JP/US/EU/Asia) HER2 low BC post chemo DESTINY-Breast04 (JP/US/EU) HER2+ NSCLC 2L~ DESTINY-Lung01 (JP/US/EU/Asia) HER2 mutated NSCLC 2L~ DESTINY-Lung02 (CN) HER2 mutated NSCLC 2L~ DESTINY-Lung05 (US/EU/Asia) NSCLC (durvalumab combo) 2L~ HUDSON (JP/US/EU) HER2+ CRC 3L DESTINY-CRC01 (JP/US/EU/Asia) HER2+ CRC 3L DESTINY-CRC02 (JP/US/EU/Asia) HER2+ BC neoadjuvant DESTINY-Breast11 (JP/US/Asia) HER2+ GC 2L DESTINY-Gastric04 (JP/US/EU/Asia) NSCLC 1L (w/ HER2 exon 19 or exon 20 mutation) DESTINY-Lung04 (JP/US/EU/Asia) NSCLC 2/3L TROPION-Lung01 (JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembro combo) 1L TROPION-Lung08 (JP/US/EU/Asia) HR+ BC 2/3L TROPION-Breast01 (JP/US/EU/Asia) TNBC 1L TROPION-Breast02 ENHERTU® Dato-DXd HER3-DXd (JP/US) EGFR mutated NSCLC (osimertinib combo) (JP/US) HER3+ BC project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials Breakthrough Designation (US) BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer (UP/US/EU/Asia) HER2 mutated tumor DESTINY-PanTumor01 (US/EU/Asia) HER2 expressing tumor DESTINY-PanTumor02 (JP/US/EU/Asia) NSCLC (w/ actionable mutation) TROPION-Lung05 (JP/US/EU/Asia) EGFR mutated NSCLC 2L (osimertinib combo) ORCHARD (JP/US/EU/Asia) EGFR mutated NSCLC 3L HERTHENA-Lung01 (JP/US/EU/Asia) EGFR mutated NSCLC 2L HERTHENA-Lung02 Daiichi-Sankyo 41#42Major R&D Pipeline: Alpha As of Jul 2022 Daiichi-Sankyo DS-7300 (JP/US) B7-H3-directed ADC ESCC, CRPC, squamous NSCLC, etc. DS-6000 (US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer DS-1055 (JP/US) Anti-GARP antibody Solid tumors DS-1211 (US) TNAP inhibitor Pseudoxanthoma elasticum DS-6016 (JP) Anti-ALK2 antibody FOP DS-7011 (US) Anti-TLR7 antibody Systemic lupus erythematosus DS-2325 (US) KLK5 inhibitor Netherton syndrome Oncology Specialty medicine Vaccine Phase 1 PLX2853 (US) BET inhibitor AML PLX2853 (US) BET inhibitor Solid tumor Phase 2 Valemetostat (DS-3201) (JP/US/EU/Asia) EZH1/2 inhibitor PTCL DS-1001 (JP) Phase 3 Filed Valemetostat (DS-3201) (JP) EZH1/2 inhibitor Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor ATL/L Quizartinib (JP/US/EU/Asia) PLX2853 (US) BET inhibitor Gynecologic neoplasms, ovarian cancer PLX2853 (US) Valemetostat (DS-3201) (EU) EZH1/2 inhibitor BCL Mutant IDH1 inhibitor. Glioma DS-7300 (JP/US/EU/Asia) B7-H3-directed ADC ES-SCLC DS-5141 (JP) ENA oligonucleotide DMD DS-5670 (JP) COVID-19 mRNA vaccine COVID-19 (initial vaccination) FLT3 inhibitor AML 1L Esaxerenone (JP) MR blocker Diabetic nephropathy VN-0102/JVC-001 (JP) Measles mumps rubella combined vaccine DS-5670 (JP) COVID-19 mRNA vaccine COVID-19 (booster vaccination) BET inhibitor Prostate cancer DS-1594 (US) Menin-MLL binding inhibitor AML, ALL DS-9606 (US/EU) Target undisclosed ADC Solid tumors VN-0200 (JP) RS virus vaccine RS virus infection project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials SAKIGAKE Designation (JP) Orphan drug designation (JP/US/EU) VN-0107/MEDI3250 (JP) Live attenuated influenza vaccine nasal spray ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma, FOP: Fibrodysplasia ossificans progressive, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, ES-SCLC: extensive stage-small cell lung cancer, PTCL: peripheral T-cell lymphoma 42#43Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1125 Email: Daiichi [email protected]